LIVIVO - Search results -

Search results

Result 1 - 10 of total 260

Search options

Article ; Conference proceedings: FAECAL MICROBIOTA TRANSPLANTATION IS A SIMPLE, EFFECTIVE AND SAFE TREATMENT IN THE MANAGEMENT OF C. DIFFICILE INFECTION IN DAILY CLINICAL PRACTICE

El Hajra Martinez, I. / Ferre Aracil, C. / Vera Mendoza, M.I. / Ramos Martínez, A. / Muñez Rubio, E. / Fernández-Cruz, A. / Matallana Royo, V. / Garcia Maseda, S. / Sanchez Romero, I. / Martinez Ruiz, R. / Blanco Rey, S. / Santos Perez, E. / Pinto Da Costa, A. / Calleja Panero, J.L.

Endoscopy

2022 Volume 54, Issue S 01

Event/congress	ESGE Days 2022, Prague, Czech Republic, 2022-04-28
Language	English
Publishing date	2022-04-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article ; Conference proceedings
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/s-0042-1744878
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improving access to SLE therapies in low and middle-income countries.

Mendoza-Pinto, Claudia / Etchegaray-Morales, Ivet / Ugarte-Gil, Manuel F

Rheumatology (Oxford, England)

2023 Volume 62, Issue Suppl 1, Page(s) i30–i35

Abstract: SLE increases disease burden in those affected with it, and that is particularly the case in low- and middle-income countries. The 2019 Addressing Lupus Pillar of Health Advancement project is a multiphase initiative whose objective is to recognize, ... ...

Abstract	SLE increases disease burden in those affected with it, and that is particularly the case in low- and middle-income countries. The 2019 Addressing Lupus Pillar of Health Advancement project is a multiphase initiative whose objective is to recognize, hierarchize and establish approaches for diligent SLE research, care and access to healthcare. Lack of access to high-cost medications that have been shown to be efficacious in the short term and that potentially reduce damage in SLE is a complex issue. In this review, we highlight opportunities and plans of action to diminish costs and improve access to therapies, which should be recognized and executed, preferably within regional strategies with multiple stakeholders (including supranational organizations, governments, the pharmaceutical industry, medical societies and the general population) connected with and grounded in structured and clear cost-effectiveness analysis.
MeSH term(s)	Humans ; Developing Countries ; Delivery of Health Care ; Cost of Illness ; Lupus Erythematosus, Systemic/drug therapy
Language	English
Publishing date	2023-03-29
Publishing country	England
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keac530
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genetic variation of FTO: rs1421085 T>C, rs8057044 G>A, rs9939609 T>A, and copy number (CNV) in Mexican Mayan school-aged children with obesity/overweight and with normal weight.

González-Herrera, Lizbeth / Zavala-Castro, Jorge / Ayala-Cáceres, Claudia / Pérez-Mendoza, Gerardo / López-González, María José / Pinto-Escalante, Doris / Canto-Cetina, Thelma / García-Escalante, María Guadalupe / Rubi-Castellanos, Rodrigo / Contreras-Capetillo, Silvina / Herrera-Sanchez, Fernando / Méndez-Domínguez, Nina / Alcocer-Gamboa, Alberto

American journal of human biology : the official journal of the Human Biology Council

2018 Volume 31, Issue 1, Page(s) e23192

Abstract: ... polymorphisms (SNPs) rs1421085T>C, rs9939609T>A, rs8057044G>A and copy number variation (CNV) was evaluated ...

Abstract	Objectives: Genetic variation of the fat mass and obesity associated gene (FTO) has been identified as a risk factor for obesity and obesity traits. Distribution of FTO single nutleotide polymorphisms (SNPs) rs1421085T>C, rs9939609T>A, rs8057044G>A and copy number variation (CNV) was evaluated in association with childhood obesity or overweight status in children with Mayan ethnicity. Methods: We included 318 school-aged children with obesity or overweight status (body mass index [BMI]: >85th percentile) and 303 children with normal weight (BMI: 15th-85th percentile). Genotyping was performed using real-time polymerase chain reaction (RT-PCR) with TaqMan probes. The cross-sectional study was carried out using univariate and multivariate logistic regression models adjusted for gender. Results: FTO-SNP rs1421085 showed significant differences between children with obesity and children with normal weight for the heterozygous genotype (P = 0.003) and for allele frequencies (P = 0.023). Adjusting by gender, significant differences were found in frequencies of the hetezygous genotype of SNPs rs9939609 (P = 0.023) and rs1421085 (P = 0.003) as well as in allele frequencies (P = 0.042 and P = 0.013, respectively) between girls with obesity and girls without obesity. In contrast, SNP rs8057044 was significantly different only between heterozygous overweight versus normal weight boys (P = 0.035) and for the allele frequency of rs8057044 (P = 0.021). The mean relative CNV was significantly higher in male overweight children than in boys with normal weight (P = 0.000). Conclusions: The FTO SNP rs1421085 is a genetic factor associated with obesity in Mayan school-aged children. FTO SNPs rs1421085 and rs9939609 affect genetic susceptibility for obesity only in girls, whereas, SNP rs8057044 and CNV are associated with overweight status only in boys.
MeSH term(s)	Adolescent ; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Body Weight/genetics ; Child ; Child, Preschool ; Cross-Sectional Studies ; Female ; Genetic Variation ; Humans ; Indians, North American/statistics & numerical data ; Male ; Mexico/epidemiology ; Overweight/epidemiology ; Overweight/genetics ; Pediatric Obesity/epidemiology ; Pediatric Obesity/genetics ; Polymorphism, Single Nucleotide ; Risk Factors
Chemical Substances	Alpha-Ketoglutarate-Dependent Dioxygenase FTO (EC 1.14.11.33) ; FTO protein, human (EC 1.14.11.33)
Language	English
Publishing date	2018-12-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1025339-7
ISSN	1520-6300 ; 1042-0533
ISSN (online)	1520-6300
ISSN	1042-0533
DOI	10.1002/ajhb.23192
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2567: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk of Diabetes Mellitus in systemic lupus erythematosus: systematic review and meta-analysis.

Etchegaray-Morales, Ivet / Mendoza-Pinto, Claudia / Munguía-Realpozo, Pamela / Solis-Poblano, Juan Carlos / Méndez-Martínez, Socorro / Ayón-Aguilar, Jorge / Abud-Mendoza, Carlos / García-Carrasco, Mario / Cervera, Ricard

Rheumatology (Oxford, England)

2024

Abstract: Objective: To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.: Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science were performed from ... ...

Abstract	Objective: To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE. Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science were performed from inception to February 2023. Cohort and cross-sectional studies that analyzed the risk of DM in patients with SLE were included. The associations between diabetes and antirheumatic agents, such as antimalarials and glucocorticoids, were analyzed in cohort studies. Data were pooled using fixed- or random-effects meta-analysis to estimate pooled odd ratios (OR), relative risks (RR), and 95% confidence intervals (CIs). This study was registered with PROSPERO (CRD42023402774). Results: A total of 37 studies (23 cross-sectional and 14 cohort studies) involving 266 537 patients with SLE were included. The pooled analyses from cross-sectional studies and cohort studies did not show an increased risk of DM in SLE patients (OR = 1.05, 95% CI 0.87-1.27; p = 0.63 and RR = 1.32, 95% CI 0.93-1.87; p= 0.12, respectively). However, several cohort studies consistently demonstrated a reduced risk of diabetes with antimalarials, while glucocorticoid use has been associated with an increased risk of developing diabetes. Age, sex, hypertension, and immunosuppressants have not been identified as risk factors for DM in SLE patients. Conclusions: Although there was no increased risk of DM in patients with SLE compared with controls, HCQ users or adherents had a decreased risk, whereas glucocorticoid users had an increased risk.
Language	English
Publishing date	2024-03-29
Publishing country	England
Document type	Journal Article
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/keae204
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis.

Dyball, Sarah / Rodziewicz, Mia / Mendoza-Pinto, Claudia / Bruce, Ian N / Parker, Ben

Autoimmunity reviews

2022 Volume 21, Issue 11, Page(s) 103184

Abstract: Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some of whom progress to a formal clinical diagnosis over ... ...

Abstract	Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some of whom progress to a formal clinical diagnosis over time. This systematic review (SR) and meta-analysis aimed to identify clinical and laboratory features and biomarkers that can predict progression of UCTD. Methods: A systematic literature search was carried out on MEDLINE, EMBASE and the Cochrane Central Register of Randomized Controlled Trials. Abstracts and full-text manuscripts were screened by two reviewers. Publications were included if they included at least 20 UCTD patients, a minimum of six months of follow up, and provided data on at least one risk factor for developing a defined CTD. The QUIPS tool was used to assess risk of bias (RoB) and GRADE for grading the quality of the evidence. The study is registered with PROSPERO (ID: CRD42021237725). Results: Fifty-nine studies were included in the SR, and forty-one in the meta-analysis. The predictors for progression to SLE with the highest certainty of evidence included those with younger age (MD -5.96 [-11.05-0.87 years]), serositis (RR 2.69 [1.61-4.51]), or the presence of anti-dsDNA antibodies (RR 4.27 [1.92-9.51]). For SSc, the highest certainty of evidence included puffy fingers (RR [3.09 [1.48-6.43]), abnormal nailfold changes (NFC) (avascular areas [RR 5.71 (3.03-10.8)] or active or late SSc pattern [RR 2.24 (1.25-4.01)] and anti-topoisomerase-I (RR 1.83 [1.45-2.30]). No novel biomarkers were included in the meta-analysis; however HLA molecules, regulatory T cell shift, pro-inflammatory cytokines and complement activation products were identified as potential predictors for evolution of disease. Conclusions: Clinical and immunological parameters may predict which patients with UCTD progress to definitive disease; however, the heterogeneous nature and RoB in most studies limits the ability to apply these results in routine clinical practice. Limited data suggest that some novel biomarkers may provide additional predictive value but these will need larger well designed studies to fully delineate their clinical utility.
MeSH term(s)	Humans ; Undifferentiated Connective Tissue Diseases ; Connective Tissue Diseases/diagnosis ; Lupus Erythematosus, Systemic/diagnosis ; Scleroderma, Systemic ; Biomarkers ; Disease Progression
Chemical Substances	anti-dsDNA autoantibody ; Biomarkers
Language	English
Publishing date	2022-08-27
Publishing country	Netherlands
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	2144145-5
ISSN	1873-0183 ; 1568-9972
ISSN (online)	1873-0183
ISSN	1568-9972
DOI	10.1016/j.autrev.2022.103184
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5913: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update.

Rodziewicz, Mia / Mendoza-Pinto, Claudia / Dyball, Sarah / Munguía-Realpozo, Pamela / Parker, Ben / Bruce, Ian N

Seminars in arthritis and rheumatism

2023 Volume 65, Page(s) 152346

Abstract: Background: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of ...

Abstract	Background: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of a systematic review of predictive and prognostic factors of anti-CD20 MAb treatment in SLE. Methods: A systematic literature search was undertaken to identify predictive and prognostic factors of clinical response following treatment with anti-CD20 therapies in SLE patients. Studies examining rituximab published prior to 2015 were excluded. Risk of bias was assessed for randomized controlled trials (RCTs) using the Cochrane Collaboration (RoB2) tool for RCTs and the Quality In Prognosis Studies Tool (QUIPS) for cohort studies. A narrative synthesis of the evidence was undertaken and quality of evidence (QoE) was assessed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: From 850 studies identified, 17 studies met the inclusion criteria. A further 8 studies were identified and included through search updates. There were two post-hoc analyses of RCTs of rituximab, one RCT of ocrelizumab and one of obinutuzumab; and 16 cohort studies examining rituximab treatment. The overall QoE was low or very low. There was wide heterogeneity in definitions of clinical disease activity and outcome measures, non-standardized laboratory cut-offs, failure to account for confounders and multiple subgroup analyses of differing outcomes. B cell depletion as well as novel biomarkers, such as S100 proteins, FCGR genotype, anti-vimentin and anti-drug antibodies showed some evidence of prognostic value but QoE was limited due to moderate to high risk of bias, early phase of investigation and imprecision of results. Conclusion: There has been no validation of previously identified prognostic factors to guide outcome in anti-CD20 treated lupus patients. Hypothesis-driven studies of several novel markers however, demonstrate prognostic value and require replication and validation to support their use in routine clinical practice. Prospero registration number: CRD42020220339.
MeSH term(s)	Humans ; Rituximab/therapeutic use ; Treatment Outcome ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/chemically induced
Chemical Substances	Rituximab (4F4X42SYQ6) ; Antibodies, Monoclonal ; Antineoplastic Agents
Language	English
Publishing date	2023-12-16
Publishing country	United States
Document type	Systematic Review ; Journal Article ; Review
ZDB-ID	120247-9
ISSN	1532-866X ; 0049-0172
ISSN (online)	1532-866X
ISSN	0049-0172
DOI	10.1016/j.semarthrit.2023.152346
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 790: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C).

García-Carrasco, M / Mendoza-Pinto, C / Cardiel, M H / Méndez-Martínez, S / García-Villaseñor, A / Jiménez-Hernández, C / Alonso-García, N E / Briones-Rojas, R / Ramos-Álvarez, G / López-Colombo, A

Lupus

2012 Volume 21, Issue 11, Page(s) 1219–1224

Abstract: The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and ... ...

Abstract	The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and social impact. We conducted a descriptive study of women aged ≥ 18 years attending our Lupus Clinic. HRQOL was assessed by applying the LupusQoL© and SF-36. Lupus activity was measured using the Mexican Systemic Lupus Erythematosus Disease Activity Index (Mex-SLEDAI) and chronic damage using the Systemic Lupus Collaborative Clinics Damage Index (SDI). Data were analyzed using descriptive statistics, the chi-square test and Pearson's product moment correlation coefficient. A total of 127 patients were included with a mean age of 40.5 ± 12.6 years. The mean disease duration was 8.2 ± 5.6 years, the mean disease activity score was 2.4 ± 3.0, and the mean SDI score 0.77 ± 1.06. The mean SF-36 score was 58.1 ± 21.1 and the mean LupusQoL© score was 69 ± 22.7. The correlation between global scores of the SF-36 and LupusQoL© was rho = 0.73 (p < 0.001). The correlation between lupus disease activity and the SF-36 and the LupusQoL© was -0.26 (p = 0.003) and -0.25 (p = 0.004), respectively. The correlation between the SDI and the SF-36 and the LupusQoL© was -0.28 (p = 0.001) and -0.38 (p < 0.0001), respectively. In conclusions: both LupusQoL© and SF-36 were useful instruments in assessing HRQOL in Mexican lupus female patients. The usefulness of the LupusQoL© should be evaluated in lupus patients with moderate to severe disease activity.
MeSH term(s)	Adult ; Chi-Square Distribution ; Cross-Sectional Studies ; Data Interpretation, Statistical ; Female ; Humans ; Lupus Erythematosus, Systemic/physiopathology ; Middle Aged ; Quality of Life ; Severity of Illness Index ; Surveys and Questionnaires
Language	English
Publishing date	2012-10
Publishing country	England
Document type	Comparative Study ; Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/0961203312456749
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease.

Escárcega, Ricardo O / García-Carrasco, Mario / Mendoza-Pinto, Claudia

Reumatologia clinica

2020 Volume 16, Issue 5 Pt 1, Page(s) 311–312

MeSH term(s)	Atherosclerosis/etiology ; Atherosclerosis/prevention & control ; Autoimmune Diseases/complications ; Autoimmune Diseases/therapy ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Humans ; Rheumatic Diseases/complications ; Rheumatic Diseases/therapy
Language	Spanish
Publishing date	2020-07-25
Publishing country	Spain
Document type	Editorial
ISSN	2173-5743
ISSN (online)	2173-5743
DOI	10.1016/j.reuma.2020.07.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Mendoza-Pinto, Claudia / García-Carrasco, Mario / Cervera, Ricard

Current rheumatology reports

2018 Volume 20, Issue 10, Page(s) 62

Abstract: ... in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be ...

Abstract	Purpose of review: The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant). Recent findings: There is an increased risk of developing aPL in various infections, particularly in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be associated with thromboembolic events, including catastrophic APS. There is a link between vaccinations, such as the tetanus toxoid and aPL, due to molecular mimicry between the two molecules. Accumulated evidence supports that the presence of aPL is associated with a variety of infections, including viruses, bacteria, fungi, and parasites, and the main mechanism to explain this correlation is molecular mimicry. Moreover, a link between vaccinations, such as the tetanus toxoid, and APS has also been described.
MeSH term(s)	Antiphospholipid Syndrome/virology ; Bacterial Infections/complications ; Hepatitis C/complications ; Humans ; Tetanus/complications ; Virus Diseases/complications
Language	English
Publishing date	2018-08-20
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057357-1
ISSN	1534-6307 ; 1523-3774
ISSN (online)	1534-6307
ISSN	1523-3774
DOI	10.1007/s11926-018-0773-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Therapeutic options for the management of severe COVID-19: A rheumatology perspective.

Mendoza-Pinto, Claudia / García-Carrasco, Mario / Munguía Realpozo, Pamela / Méndez-Martínez, Socorro

Reumatologia clinica

2020 Volume 17, Issue 8, Page(s) 431–436

Abstract: The novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). Acute respiratory distress syndrome (ARDS), multiorgan dysfunction and thrombotic events are among the leading causes of death in ... ...

Abstract	The novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). Acute respiratory distress syndrome (ARDS), multiorgan dysfunction and thrombotic events are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a "cytokine storm", also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. In addition to anti-viral therapy and supportive treatment in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed therapeutic options, including the antibody therapy that might be an immediate strategy for SARS-CoV-2 therapy.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19/therapy ; Chloroquine/therapeutic use ; Combined Modality Therapy ; Cytokine Release Syndrome/diagnosis ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/therapy ; Cytokine Release Syndrome/virology ; Fibrinolytic Agents/therapeutic use ; Glucocorticoids/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; Immunization, Passive ; Immunoglobulins, Intravenous/therapeutic use ; Immunologic Factors/therapeutic use ; Plasma Exchange ; Protein Kinase Inhibitors/therapeutic use ; Respiratory Therapy ; Rheumatology ; Severity of Illness Index ; Thrombosis/drug therapy ; Thrombosis/virology
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Fibrinolytic Agents ; Glucocorticoids ; Immunoglobulins, Intravenous ; Immunologic Factors ; Protein Kinase Inhibitors ; Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF) ; tocilizumab (I031V2H011)
Language	English
Publishing date	2020-10-15
Publishing country	Spain
Document type	Journal Article ; Review
ISSN	2173-5743
ISSN (online)	2173-5743
DOI	10.1016/j.reumae.2020.05.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED